Therapeutic roles of peroxisome proliferator-activated receptor agonists.
about
Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?Honokiol: a non-adipogenic PPARγ agonist from natureParallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgammaDual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.Role of Peroxisome Proliferator-Activated Receptor γ in Ocular DiseasesRosiglitzone suppresses angiotensin II-induced production of KLF5 and cell proliferation in rat vascular smooth muscle cellsSulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacyStructural basis for telmisartan-mediated partial activation of PPAR gammaMetabolic syndrome, inflammation and atherosclerosisComparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytesAtheroprotective effect of oleoylethanolamide (OEA) targeting oxidized LDLEffect of chronic treatment with Rosiglitazone on Leydig cell steroidogenesis in rats: in vivo and ex vivo studiesThe impact of PPARα activation on whole genome gene expression in human precision cut liver slicesComparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytesE4orf1: a novel ligand that improves glucose disposal in cell cultureAre thiazolidinediones good or bad for the heart?Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma.Ligand modulated antagonism of PPARgamma by genomic and non-genomic actions of PPARdelta.The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats.Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterolAnticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.The role of toxicoproteomics in assessing organ specific toxicity.Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic DrugsPioglitazone treatment reduces adipose tissue inflammation through reduction of mast cell and macrophage number and by improving vascularity.Activated Monocytes Enhance Platelet-Driven Contraction of Blood Clots via Tissue Factor ExpressionGene-nutrient interactions with dietary fat modulate the association between genetic variation of the ACSL1 gene and metabolic syndromePioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin.Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.Thiazolidinedione treatment and constitutive-PPARgamma activation induces ectopic adipogenesis and promotes age-related thymic involution.CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models.Atherogenic dyslipidemia and diabetes mellitus: what's new in the management arena?Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism.Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver.Low high-density lipoprotein cholesterol: current status and future strategies for management.Genetic loss or pharmacological blockade of testes-expressed taste genes causes male sterility.Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor γ co-activator-1α protein.Adipose gene expression profiles related to metabolic syndrome using microarray analyses in two different models.Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trialsPharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study.Discontinued in 2013: diabetic drugs.
P2860
Q24564203-079B86E1-43BE-465A-99B1-30398E6A729AQ24614114-453BF79B-4722-4DBE-ABC9-8E49E7A88A48Q24685818-75906E35-28C0-4BA5-A7EC-A04237557253Q24816834-54E7E383-9E10-49EE-AEBD-A74F6B356233Q27022548-7B506098-3329-47F9-86FC-4989640A4665Q27309387-EF429C53-7FF7-419E-89A6-135ED90A07E1Q27666968-7782EA5B-E1BD-4BD9-8B37-64D12E457AE5Q27677426-9C920656-C274-4EED-871B-8ED9A28D10AEQ28219348-3FD7C063-6106-4B45-B0E3-70B6EE9C23B5Q28477796-7DBFBF6D-906B-4A46-9427-7F29BCC0654DQ28538861-6303E465-6E98-4419-90DD-63EB0BEED18FQ28575457-097B0FBA-2796-4E7E-BF10-683F49DEE6AEQ28606579-8151DCEB-95BC-468C-BBCD-BE8E45CC4AD9Q28730590-B703AEE6-918A-4E45-87D8-810B241106BBQ28741118-245C5F20-E2CB-4296-9184-A8BB813368ABQ30435005-2E2146D8-5C26-4A82-8356-69770DA40316Q33347137-DB255BC2-CDC9-47A4-8F1E-79D4BB9DF086Q33503634-80AD5A3D-7BA5-41DD-A92C-20FF3C6B4ECCQ33552642-A277F683-D93A-4DE0-B2D7-43A15CBA2A83Q33660599-A6F11B69-E983-4749-8F2A-EA73103C52D7Q33692555-3C3D340F-7B9E-4593-B318-95B33E404900Q33786700-C6172773-6043-4FDA-804C-854FC65AF7E9Q33809886-BA74DC4B-D04F-457A-86B5-3FF3B7253151Q33882669-ABE509B5-3193-4207-BD9B-65868767DCD2Q33894973-88CF59EF-B74F-480F-B4C4-4BB97CCC6F0EQ33902018-FBB0E756-DAAB-41E9-B8DA-D1B5CECD34E2Q33960995-C5121144-B6AD-4E9C-B1DB-79F2C2AAE72EQ34006864-D48196A9-04F8-4CD7-B982-4F63529BCFA7Q34020483-0D8CA8AE-684D-4917-A7F7-F72E7854B7A4Q34067485-205C5365-FCA8-4E2D-B97D-6C6D6C70C44FQ34139042-49792A00-42B0-4FCC-98C1-6214FAE45E88Q34206025-E88A9AB3-B320-40B8-A530-92C9520CFF6FQ34235817-D2451B98-3D16-4653-93A6-01B1B34E6B54Q34334846-C0F80AC2-6666-4E15-BD05-355D2A90C7D8Q34354914-54854C3B-7887-4797-933C-08A1A7A513ABQ34356092-8F2EAA21-8B32-4A9F-9F6B-6A93079BEE9AQ34404024-C8F5531A-7B92-4309-9FCA-2BFAEB7C0875Q34428524-9BD533FB-5C59-4E81-B1A4-92EBF610A607Q34618210-19813E89-6E26-4AAC-923D-883EDBD3B9BAQ34664870-FAAAD533-1DB5-451B-957C-A3CB260BE4F4
P2860
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
@ast
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
@en
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
@nl
type
label
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
@ast
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
@en
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
@nl
prefLabel
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
@ast
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
@en
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
@nl
P1433
P1476
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
@en
P304
P356
10.2337/DIABETES.54.8.2460
P407
P577
2005-08-01T00:00:00Z